Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts - Concepedia

Concepedia

Publication | Open Access

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts

DOI Full Paper Access

32

Citations

30

References

2021

Year

L Derikx, Heather W Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S Rees, Mathew Lyons, Spyros I. Siakavellas, Nathan Constantine‐Cooke, Philip Jenkinson, Shanna Su,

Journal of Crohn s and Colitis

Abstract

Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months of follow-up.

References

	Year	Citations

Page 1